IP Library › Granted Patent US 11,246,922
Granted Patent B1
US 11,246,922 · App. 17/245,535 · Granted Feb 15, 2022

Vaccine RNA-peptide against SARS-CoV-2 with endogenous exosomes as carrier

Inventor: Luis Cruz Rodriguez (Tampa, FL)
Assignee: Elidan America, LLC.
A61K39/215A61K38/45A61P31/14A61K2039/6018A61K2039/6031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,922
App. No.
17/245,535
Granted
Feb 15, 2022
Kind
B1
Abstract

A vaccine RNA-peptide against SARS-CoV-2, which has a messenger ribonucleic acid (mRNA) having an open reading frame encoding a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein. The peptide of the severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein is fused to a synthetic poly ADP-ribose polymerase peptide. The vaccine RNA-peptide against SARS-CoV-2 has endogenous exosomes as carrier.

Claims (14)

1. A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having an amino acid sequence of SEQ ID NO: 2 wherein endogenous exosomes act as carrier.

2. The composition against SARS-CoV-2 according to claim 1 , wherein the miRNA comprises a poly-A sequence.

3. The composition against SARS-CoV-2 according to claim 1 , wherein the poly-A sequence is about 10 adenosine nucleotides.

4. The composition against SARS-CoV-2 according to claim 1 , wherein the miRNA comprises the nucleic acid sequence of SEQ ID NO: 1.

5. The composition against SARS-CoV-2 according to claim 1 , wherein the peptide of the SARS-CoV-2 surface protein of SEQ ID: 2 is fused to a synthetic poly ADP-ribose polymerase peptide.

6. A method for stimulating an immune response against SARS-CoV-2 in a subject comprising administering to said subject an effective amount of the composition of claim 1 .

7. A composition against SARS-CoV-2, comprising a micro ribonucleic acid (miRNA) fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein having the amino acid sequence of SEQ ID NO: 2 fused to a synthetic poly ADP-ribose polymerase peptide.

8. The composition against SARS-CoV-2 according to claim 7 , wherein the miRNA comprises a poly-A sequence.

9. The composition against SARS-CoV-2 according to claim 7 , wherein the poly-A sequence is about 10 adenosine nucleosides.

10. The composition against SARS-CoV-2 according to claim 7 , wherein the miRNA comprises the nucleic acid sequence of SEQ ID NO: 1.

11. The composition against SARS-CoV-2 according to claim 7 , wherein the synthetic poly ADP-ribose polymerase peptide comprises the amino acid sequence of SEQ ID NO: 3.

12. The composition against SARS-CoV-2 according to claim 7 , wherein the micro ribonucleic acid (miRNA) is fused to a peptide that comprises the amino acid sequence of SEQ ID NO: 4.

13. A method for stimulating an immune response against SARS-CoV-2 in a subject in need thereof comprising administering to said subject an effective amount of the composition of claim 7 .

14. A composition against SARS-CoV-2 comprising a micro ribonucleic acid (miRNA) having a nucleic acid sequence of SEQ ID NO: 1 fused to a peptide of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) surface protein fused to a synthetic poly ADP-ribose polymerase peptide that comprises the amino acid sequence of SEQ ID NO: 4, wherein endogenous exosomes act as carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2021
From: CRUZ RODRIGUEZ, LUIS, MR.
To: ELIDAN AMERICA, LLC.
Reel/Frame 056097/0541 →
Cited By (2)
US 12,202,857 US 12,411,064